The systems are operated by the public Institut Mohamed Kassab d’Orthopédie and the private Centre d'Imagerie Médicale Ariana in the Tunis metropolitan area.

The Institut Mohamed Kassab d’Orthopédie is a center of excellence in Tunisia for orthopedic surgery, treating adults and children with advanced techniques.

The Centre d'Imagerie Médicale Ariana, founded in 1992, has a comprehensive radiological suite, including numerous modalities and a staff of 30, of which 4 are radiologists.

EOS imaging will also be attending the Journées Francophones de Radiologie (JFR) meeting, to be held October 14-17 in Paris, France. JFR is the second largest gathering of radiologists in Europe and attracts over 17,000 attendees from 80 different countries, including numerous physicians from Africa.

During the JFR meeting, EOS imaging will share with radiologists its solutions to increase the role of image-based reports and data in the orthopedic care pathways.

This includes, next to the Company’s biplanar low dose equipment: easy access to 3D models and patient-specific data sets through the new EOS 3D services suite; tools for seamless exchange between radiologists and referring orthopedic surgeons; and on line 3D surgical planning solutions (EOSapps) for the spine, hip and knee. Demonstrations of the products will be available at the Company’s booth #113.

Marie Meynadier, CEO of EOS imaging, said, “It’s always exciting when an up-and-coming market adopts the EOS technology. With the opening of these two new sites in Tunisia, providers in North Africa will now have access to reference centers to learn about EOS as they are looking to equip their imaging departments with state of the art, safe and precise imaging.

“The JFR meeting is also a great forum for sharing with radiologists from Europe and Africa our newest developments and contribute to the strengthening of their relationships with referring surgeons.”

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States, Japan, China, and the European Union.